-

Parnell Appoints Sharon Holt as Vice President of U.S. Pet Care

Experienced animal health leader brings more than two decades of commercial, operational and strategic expertise to accelerate growth in companion animal business

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Parnell today announced the appointment of Sharon Holt as Vice President of U.S. Pet Care, strengthening the company's leadership team as it continues to expand its companion animal portfolio and commitment to veterinary customers.

Holt joins Parnell with more than 20 years of experience in the animal health industry. Since joining Merial in 2002 and continuing through its acquisition by Boehringer Ingelheim in 2017, she has held leadership positions spanning sales, marketing, supply chain, commercial operations and business development. Throughout her career, she has helped drive organizational growth, operational excellence and customer-focused innovation that supports veterinarians, pet owners and the health of pets.

Most recently, Holt was recognized by Boehringer Ingelheim for her leadership and impact, receiving the OnePet Innovation Award and the Global Excellence Award in 2025, followed by the President's Club Award in 2026.

In her role at Parnell, Holt will lead the company's U.S. Pet Care business, focusing on commercial strategy, customer engagement, organizational development and growth initiatives designed to expand access to innovative solutions for veterinary professionals and the animals they serve.

“Sharon is a highly respected leader with a proven track record of delivering results, building high-performing teams and creating meaningful value for customers,” said Pablo Lamberto, DVM, U.S. General Manager at Parnell. “Her deep understanding of the companion animal market, combined with her passion for customer success and innovation, makes her an outstanding addition to the Parnell leadership team. We are excited to welcome Sharon as we continue investing in our Pet Care business and supporting veterinarians across the United States.”

About Parnell

Parnell is a veterinary pharmaceutical company focused on developing, manufacturing, and commercializing animal health solutions across anesthesia and beyond. With a strong commitment to quality and customer partnerships, Parnell manufactures and markets products for companion and production animals in 10 countries. Learn more at www.parnell.com.

©2026 Parnell Technologies Pty LTD. MKT-26-170 PC US

Contacts

Media Contact:

Angela Kille
Associate Director of Strategic Marketing
angela.kille@parnell.com
913‑274‑2100

Parnell


Release Versions

Contacts

Media Contact:

Angela Kille
Associate Director of Strategic Marketing
angela.kille@parnell.com
913‑274‑2100

Social Media Profiles
More News From Parnell

Parnell Expands PropofolVet Multidose Offering with New 50 mL Presentation

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Parnell today announced the availability of a new 50 mL presentation of PropofolVet Multidose (propofol injectable emulsion), providing veterinary professionals with an additional option to support anesthesia protocols while helping optimize inventory management and reduce waste. The new presentation complements the existing 20 mL offering, extending the reach of Parnell's first generic propofol injectable emulsion for dogs.PropofolVet Multidose is indicated...

Parnell Adds Sevoflurane to Its Growing Veterinary Anesthesia Portfolio

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Parnell today announced the launch of Sevoflurane Inhalation Anesthetic, expanding its anesthesia portfolio to better support veterinary teams across the full procedural workflow. Indicated for the induction and maintenance of general anesthesia in dogs, the new offering provides clinics with a reliable, cost-effective inhalant anesthetic option from a company veterinary teams already rely on. The addition reinforces Parnell’s commitment to delivering confi...

Parnell Acquires Noble Pharma LLC, Expanding U.S. Manufacturing Capabilities

SYDNEY, Australia--(BUSINESS WIRE)--Parnell today announced the acquisition of Noble Pharma LLC, a U.S.-based pharmaceutical manufacturer, according to the Securities Purchase Agreement dated November 26, 2025. With this strategic acquisition, Parnell strengthens its U.S. operations and further advances its long-term commitment to delivering high‑quality products, reliable supply, and an enhanced level of support to its customers and distribution partners. Noble Pharma significantly enhances Pa...
Back to Newsroom